NJ Judge Won't Toss FCA Suit Over J&J Unit's Cancer Drug
By Jeannie O'Sullivan (December 20, 2021, 3:41 PM EST) -- A New Jersey federal judge refused to release a Johnson & Johnson pharmaceutical unit and affiliates from a patent attorney's False Claims Act lawsuit over the prostate cancer treatment Zytiga, reasoning that the lawyer adequately alleged that the company obtained a patent under false pretenses.
In a ruling Friday, U.S. District Judge Kevin McNulty said plaintiff Zachary Silbersher met the pleading requirements for his claims that Janssen Biotech Inc. and affiliates reaped $2.5 billion in Zytiga sales, with a "significant" portion of the riches coming from government insurance programs, before the eventual invalidation of its patent.
Silbersher's lawsuit alleged Janssen won...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!